Nacif v. Athira Pharma Inc

CourtDistrict Court, W.D. Washington
DecidedFebruary 15, 2024
Docket2:21-cv-00861
StatusUnknown

This text of Nacif v. Athira Pharma Inc (Nacif v. Athira Pharma Inc) is published on Counsel Stack Legal Research, covering District Court, W.D. Washington primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Nacif v. Athira Pharma Inc, (W.D. Wash. 2024).

Opinion

1 2 UNITED STATES DISTRICT COURT WESTERN DISTRICT OF WASHINGTON 3 AT SEATTLE 4 ANTONIO BACHAALANI NACIF; WIES RAFI; and HANG GAO, individually and 5 on behalf of all others similarly situated, 6 Plaintiffs, C21-0861 TSZ v. 7 ORDER ATHIRA PHARMA, INC.; and LEEN 8 KAWAS, Ph.D., Defendants. 9

10 THIS MATTER comes before the Court on plaintiffs’ unopposed renewed motion 11 for preliminary approval of a proposed class settlement, docket no. 125. By Order 12 entered September 27, 2023, docket no. 123, the Court denied plaintiffs’ previous 13 motion, docket no. 118, for preliminary approval of a proposed class settlement because 14 (i) an intraclass conflict of interest existed, and (ii) the proposed settlement could not be 15 certified as “treat[ing] class members equitably relative to each other.” Order at 5–9 16 (docket no. 123) (quoting Fed. R. Civ. P. 23(e)(2)(D)). The parties have since engaged in 17 further settlement negotiations and have entered into an Amended Stipulation and 18 Agreement of Settlement (“Settlement Agreement”), docket no. 125-2. Having reviewed 19 the Settlement Agreement, the pending motion, and the other materials submitted by the 20 parties, the Court enters the following Order granting the motion in part, preliminarily 21 approving the proposed settlement, certifying a class and two subclasses, deferring in part 22 as to the proposed notices and claim form, requiring submission of an opt-out (exclusion 1 Discussion 2 As indicated in the Court’s earlier Order, this case involves publicly traded

3 common stock of defendant Athira Pharma, Inc. (“Athira”), some of which was acquired 4 in connection with Athira’s initial public offering (“IPO”) in September 2020, some of 5 which was purchased when Athira conducted a secondary public offering (“SPO”) 6 in January 2021, and some of which cannot be traced to either the IPO or the SPO. 7 In response to the Court’s inquiries, see Order at 11–12 (docket no. 123); Minute Order 8 at ¶ 1(a)(i) (docket no. 119), the parties have clarified that all Athira shares issued before

9 the IPO (and SPO) were subject to lock-up or market-stand-off restrictions that prevented 10 their trading until the market opened on March 17, 2021. See Duncan Decl. at ¶¶ 3–8 11 (docket no. 125-7). Based on this information, the parties have substantially simplified 12 their traceability analysis for purposes of the claims in this litigation, which are now as 13 follows:

14 Securities Act Claims: Claims relating to Athira’s publicly traded common stock acquired during the period from September 17, 2020, 15 through March 16, 2021; such claims are brought pursuant to Sections 11, 12(a)(2), and 15 of the Securities Act of 1933 (“Securities Act”), 15 U.S.C. 16 §§ 77k, 77l, and 77o; and 17 Exchange Act Claims: Claims relating to Athira’s publicly traded common stock acquired during the period from March 17, 2021, through 18 June 17, 2021; such claims were asserted under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (“Exchange Act”), 15 U.S.C. 19 §§ 78j(b) & 78t(a), and United States Securities and Exchange Commission (“SEC”) Rule 10b-5, 17 C.F.R. § 240.10b-5. 20 See Pl.’s Renewed Mot. at 5–6 (docket no. 125); see also Am. Compl. (docket no. 74). 21 In other words, the Securities Act Claims relate to Athira shares traceable to the IPO and 22 SPO, and the Exchange Act Claims concern Athira shares purchased after the lock-up 1 period expired and before “corrective information” was disclosed. See Nye Decl. at ¶ 8 2 (docket no. 125-5); see also Am. Compl. at ¶ 91 (docket no. 74) (quoting a press release

3 issued by Athira after the market closed on June 17, 2021). 4 A. Joinder 5 In addition to involving separate timeframes, the two types of claims in this matter 6 differ with regard to their litigation status. Although some portions of the Securities Act 7 Claims remain viable, the Exchange Act Claims have been dismissed, see Order (docket 8 no. 89), and they have not been repleaded by the lead plaintiffs, Antonio Bachaalani

9 Nacif and Wies Rafi. See Order at 2–4 (docket no. 123) (reciting the procedural history 10 of these claims and observing that the “decision not to timely amend [the] operative 11 pleading renders ‘final’ the earlier dismissal without prejudice” (quoting Order at 5 12 (docket no. 114))). As a result, Nacif’s and Rafi’s positions are not “typical” of those of 13 the absent class members. See Order at 5–7 (docket no. 123) (citing Epstein v. MCA,

14 Inc., 179 F.3d 641, 652–53 (9th Cir. 1999) (Thomas, C.J., dissenting)); see also Fed. R. 15 Civ. P. 23(a)(3) & (e)(2)(A). To cure this inherent conflict of interest, the parties propose 16 to add Hang Gao as a named plaintiff. See Stlm’t Agr. at ¶ 1(hh) (docket no. 125-2 at 17 13). Gao’s attorneys participated in a mediation session conducted on November 16, 18 2023, and signed the Settlement Agreement on Gao’s behalf. See Melnick Decl. at 1 n.1

19 & ¶ 11 (docket no. 125-4); Stlm’t Agr. at 40 (docket no. 125-2 at 42). 20 Gao was one of two individuals who commenced this action, see Compl. (docket 21 no. 1), but Gao did not thereafter seek appointment as a lead plaintiff, see Order (docket 22 no. 60). According to a certification filed with the original complaint, Gao purchased 1 and another 100 shares of Athira stock on March 25, 2021, at the price of $17.00 per 2 share. See Pl.’s Certif. (docket no. 1-1 at 3); see also Am. Compl. at ¶ 90 (docket no. 74).

3 Thus, Gao has both Securities Act Claims and Exchange Act Claims, but unlike Nacif 4 and Rafi, Gao is not bound by the decision not to replead the Exchange Act Claims and 5 does not have interests that are antagonistic toward or in conflict with those of absent 6 putative class members. The Court treats the pending motion as seeking leave to amend 7 to join Gao as a named plaintiff and hereby GRANTS the request. 8 B. Allocation

9 The parties propose to settle both the Securities Act Claims and the Exchange Act 10 Claims on the following terms. Defendants would deposit the gross settlement amount of 11 $10 million into an interest-bearing escrow account. Attorney’s fees (predicted to be 12 33⅓% of the gross amount), litigation costs (capped at $205,000), awards to the named 13 plaintiffs (no more than $30,000), settlement administration fees (estimated to be

14 $200,000), taxes (approximately $200,000), and escrow account fees1 would be deducted 15 before the remaining net settlement proceeds (roughly $6-to-6.5 million, depending on 16 interest rates and the Court’s rulings on requests for attorney’s fees, etc.) would be 17 distributed to class members. The method for calculating the amount due to each class 18 member, denominated by the parties as the “Plan of Allocation,” is not a provision of the

19 Settlement Agreement, and defendants have expressly disavowed any involvement in the 20 21 1 In their Joint Status Report dated June 30, 2023, the parties indicated that escrow account fees would be about $5,200 per year. See JSR at 21 (docket no. 122). The current motion and related 22 documents, including the proposed notice, do not mention escrow account fees. The parties have, however, deducted the escrow account fees in calculating the probable value of the net 1 disbursement process. See Stlm’t Agr. at ¶ 21 (docket no. 125-2 at 26) (indicating that 2 defendants may not object to, and will have no “liability, obligation, or responsibility

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
Nacif v. Athira Pharma Inc, Counsel Stack Legal Research, https://law.counselstack.com/opinion/nacif-v-athira-pharma-inc-wawd-2024.